Glenview Trust Co Has $11.04 Million Stake in Becton, Dickinson and Company $BDX

Glenview Trust Co reduced its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 31.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 58,986 shares of the medical instruments supplier’s stock after selling 27,531 shares during the quarter. Glenview Trust Co’s holdings in Becton, Dickinson and Company were worth $11,040,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Gilbert & Cook Inc. lifted its holdings in Becton, Dickinson and Company by 2.0% during the 2nd quarter. Gilbert & Cook Inc. now owns 2,844 shares of the medical instruments supplier’s stock valued at $490,000 after purchasing an additional 56 shares during the last quarter. Mendel Money Management increased its holdings in shares of Becton, Dickinson and Company by 2.6% during the second quarter. Mendel Money Management now owns 2,254 shares of the medical instruments supplier’s stock worth $388,000 after buying an additional 58 shares in the last quarter. Focus Financial Network Inc. raised its stake in shares of Becton, Dickinson and Company by 2.2% in the third quarter. Focus Financial Network Inc. now owns 2,692 shares of the medical instruments supplier’s stock valued at $504,000 after acquiring an additional 58 shares during the last quarter. Phillips Wealth Planners LLC boosted its holdings in shares of Becton, Dickinson and Company by 2.7% in the 3rd quarter. Phillips Wealth Planners LLC now owns 2,241 shares of the medical instruments supplier’s stock worth $430,000 after acquiring an additional 58 shares in the last quarter. Finally, CX Institutional grew its position in Becton, Dickinson and Company by 3.6% during the 3rd quarter. CX Institutional now owns 1,731 shares of the medical instruments supplier’s stock worth $324,000 after acquiring an additional 60 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insider Activity

In other news, EVP Michael David Garrison sold 1,610 shares of the company’s stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $207.46, for a total value of $334,010.60. Following the completion of the sale, the executive vice president directly owned 12,095 shares of the company’s stock, valued at $2,509,228.70. This represents a 11.75% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In the last three months, insiders sold 2,463 shares of company stock worth $501,530. 0.40% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on BDX. Citigroup cut their price objective on Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating for the company in a research report on Tuesday, February 10th. Barclays began coverage on Becton, Dickinson and Company in a research note on Tuesday, February 10th. They issued an “overweight” rating and a $202.00 target price for the company. Stifel Nicolaus upped their price target on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. Wells Fargo & Company lowered their price objective on shares of Becton, Dickinson and Company from $184.00 to $157.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 10th. Finally, Wall Street Zen lowered shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Five research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $195.46.

Becton, Dickinson and Company Stock Down 1.0%

Shares of NYSE:BDX opened at $175.95 on Tuesday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.05 and a quick ratio of 0.58. The stock has a market cap of $50.10 billion, a price-to-earnings ratio of 28.70, a P/E/G ratio of 2.30 and a beta of 0.25. The company has a 50 day moving average of $198.55 and a 200-day moving average of $192.32. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $185.02.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.81 by $0.10. The firm had revenue of $5.25 billion for the quarter, compared to analysts’ expectations of $5.15 billion. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The business’s revenue for the quarter was up 1.6% on a year-over-year basis. During the same period last year, the firm earned $3.43 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. On average, sell-side analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company declared that its Board of Directors has authorized a share repurchase program on Tuesday, January 27th that permits the company to buyback $10.00 million in outstanding shares. This buyback authorization permits the medical instruments supplier to repurchase up to 0% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s leadership believes its stock is undervalued.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th will be issued a dividend of $1.05 per share. The ex-dividend date is Tuesday, March 10th. This represents a $4.20 dividend on an annualized basis and a yield of 2.4%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 68.52%.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.